| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6500814 | WYETH PHARMS INC | Hormonal contraceptive |
Sep, 2018
(5 years ago) | |
Lybrel is owned by Wyeth Pharms Inc.
Lybrel contains Ethinyl Estradiol; Levonorgestrel.
Lybrel has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Lybrel are:
- US6500814
Lybrel was authorised for market use on 22 May, 2007.
Lybrel is available in tablet;oral dosage forms.
Lybrel can be used as prevention of pregnancy.
The generics of Lybrel are possible to be released after 03 September, 2018.
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 22 May, 2007
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
How can I launch a generic of LYBREL before it's drug patent expiration?
More Information on Dosage
LYBREL family patents
